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Floortje Mols, PhD 1,2; Dounya Schoormans, PhD1; Ignace de Hingh, PhD, MD2,3; Simone Oerlemans, PhD2; and
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BACKGROUND: The aims of this study were to prospectively assess symptoms of anxiety and depression among survivors of colorec-
tal cancer (CRC), to compare these survivors with a normative population, and to identify subgroups at risk for experiencing symp-
toms of anxiety and/or depression across a 4-year time period. Also, the impact on health-related quality of life (HRQOL) was
studied. METHODS: The population-based Eindhoven Cancer Registry was used to select patients diagnosed with CRC between
2000 and 2009. The Hospital Anxiety and Depression Scale and the European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire Core 30 (HRQOL) were completed by patients in 2010 (n52625 [73% response rate]), 2011, 2012, and
2013 and by an age- and sex-matched normative sample (n5315) in 2011. RESULTS: Patients reported a significantly higher preva-
lence of depression (19.0% vs 12.8%) and anxiety (20.9% vs 11.8%) in comparison with the norm. Anxiety was stable, whereas depres-
sion scores changed over time, although this was not clinically relevant. A longer time since diagnosis was associated with fewer
depressive symptoms over time, whereas older age and being male were associated with less anxiety and more depression. Being
married was associated with less anxiety and depression, and a low education level and comorbid conditions were associated with
more anxiety and depression. Higher levels of symptoms of depression and anxiety were associated with a lower global quality of life
and lower physical, role, cognitive, emotional, and social functioning over time. CONCLUSIONS: Because of the increased prevalence
of depression and anxiety among patients with CRC and their negative effect on HRQOL, screening and referral are of the utmost
importance, especially among those who are single, have a low educational level, and have comorbid conditions, even years after
diagnosis and treatment. Cancer 2018;124:2621-8. VC 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of Ameri-
can Cancer Society. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for com-
mercial purposes.
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INTRODUCTION
Although survival rates for patients with colorectal cancer (CRC) are relatively high (58% are alive> 10 years after their
diagnosis),1 a large proportion of this group is confronted with continuing physical and psychosocial problems because of
the cancer and its treatment.2 This could have a negative impact on their health-related quality of life (HRQOL).3
Although considerable attention is paid in the literature to the physical side effects of CRC and its treatment,4 there is less
focus on the psychosocial problems among CRC survivors. A recent review concluded that very few studies focused on
symptoms of anxiety and depression among long-term CRC survivors.5 The authors, therefore, argued that further
research is needed to establish predictors of mental health outcomes in long-term CRC survivors.5 They also pointed out
that many studies included relatively small sample sizes, were cross-sectional, contained little information on cancer treat-
ment, and did not include all disease stages and that a comparison with a normative population was often lacking.5
Therefore, we performed secondary analyses of our large population-based, longitudinal study of stage I to IV CRC
survivors diagnosed between 1 and 10 years ago at the time of study inclusion. We included clinical data and compared
our results with a normative population. The goals of this study were 1) to compare the baseline prevalence of anxiety and
depression among CRC survivors with an age- and sex-matched normative population; 2) to prospectively assess the
Corresponding author: Floortje Mols, Center of Research on Psychology in Somatic Diseases, Department of Medical and Clinical Psychology, Tilburg University,
PO Box 90153, 5000 LE Tilburg, the Netherlands; F.Mols@tilburguniversity.edu
1Center of Research on Psychology in Somatic Diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, the Netherlands; 2Netherlands
Comprehensive Cancer Organization, Netherlands Cancer Registry, Utrecht, the Netherlands; 3Department of Surgery, Catharina Hospital, Eindhoven, the Nether-
lands; 4Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom
Additional supporting information may be found in the online version of this article.
DOI: 10.1002/cncr.31369, Received: January 8, 2018; Revised: March 5, 2018; Accepted: March 8, 2018, Published online April 6, 2018 in Wiley Online Library
(wileyonlinelibrary.com)
Cancer June 15, 2018 2621
Original Article
course of symptoms of anxiety and depression over a 4-
year period; 3) to identify subgroups with high, fluctuat-
ing, and low levels of anxiety and depression over time;
and 4) to assess the impact of having symptoms of anxiety
and depression on HRQOL.
MATERIALS AND METHODS
Participants
A longitudinal, population-based cohort study was per-
formed among CRC survivors registered within the Neth-
erlands Cancer Registry, which records data on all
patients newly diagnosed with cancer. We selected
patients in the southern part of the Netherlands, an area
with 2.4 million inhabitants.6 All patients diagnosed with
stage I to IV CRC between 2000 and 2009 were eligible.
Patients who had unverifiable addresses, had a cognitive
impairment, died before the start of study or were termi-
nally ill, had stage 0 disease/carcinoma in situ, or were
already included in our 2009 CRC study or another study
(n5 169) were excluded. A complete overview of the
selection of patients can be found on our Web site under
data and documentation (https://www.dataarchive.profi-
lesregistry.nl/study_units/view/22).
Ethical approval for the study was obtained from the
medical ethics committee of the Maxima Medical Centre
in Veldhoven, the Netherlands (approval number 0822).
All participants gave informed consent.
Data Collection
Data collection was performed within Patient-Reported
Outcomes Following Initial Treatment and Long-Term
Evaluation of Survivorship (PROFILES).7 The study
started in December 2010 (time 1 [T1]), and respondents
received yearly subsequent questionnaires in 2011 (time 2
[T2]), 2012 (time 3 [T3]), and 2013 (time 4 [T4]). In
2010, survivors received a letter from their (former)
attending specialist to inform them about the study. The
letter included a link to a secure Web site, a login name,
and a password so that interested patients could provide
consent and complete questionnaires online. Those who
preferred written communication could return a postcard,
after which they received our paper and pencil informed
consent form and questionnaire. Nonrespondents were
sent a reminder letter and a paper and pencil question-
naire within 2 months.
Sociodemographic and Clinical Characteristics
Information on survivors’ sociodemographic and clinical
characteristics was available from the Netherlands Cancer
Registry. Other relevant sociodemographic and clinical
factors were obtained through the questionnaires (eg,
marital status, educational level, and current occupation).
Comorbidity in the last 12 months was assessed with the
adapted Self-Administered Comorbidity Questionnaire.8
Symptoms of Anxiety and Depression
We used the Hospital Anxiety and Depression Scale
(HADS) to assess self-reported symptoms of anxiety and
depression.9 The HADS consists of 14 items: 7 items for
depressive symptoms and 7 items for anxiety. It assesses
levels of symptoms in the last week. The questions can be
answered on a 4-point Likert scale, and the total score for
each scale can range from 0 to 21. The cutoff value for
symptoms of anxiety and depression is indicated by a
score 8.9-11
HRQOL
The European Organisation for Research and Treatment
of Cancer (EORTC) Quality of Life Questionnaire Core
30 (QLQ-C30; version 3.0) was used to assess cancer-
specific HRQOL.12 It contains 5 functional scales, the
Global Quality of Life scale, 3 symptom scales, and 6 sin-
gle items. The symptom scales and single items were not
used in this study. Each item is scored on a 4-point Likert
scale except for the Global Quality of Life scale, which has
a 7-point Likert scale. Scores are linear-transformed to a 0
to 100 scale.13 A higher score on the functional scales and
Global Quality of Life scale means better functioning and
HRQOL.
Normative Population
Norm data were obtained in 2011 from the Health and
Health Complaints project from CentERdata (https://
www.centerdata.nl/). It is representative of the Dutch-
speaking population in the Netherlands and includes
those without Internet access. Panel members who were
18 years old or older received an online version of the
HADS, the EORTC QLQ-C30, and the Self-
Administered Comorbidity Questionnaire. Nonrespond-
ents were reminded a week later. In total, 2040 panel
members (82%) responded. An age- and sex-matched
normative sample without cancer (1 person per panel-
household) was selected from this group to match the age
and sex distribution of the CRC sample. For matching,
10 strata were formed with sex and age (5 categories).
Within each stratum, a maximum number of persons
from the reference cohort were randomly matched accord-
ing to the strata frequency distribution of patients. This
resulted in 315 matched cancer-free individuals for the
2625 CRC survivors.
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Statistical Analyses
Differences in baseline sociodemographic and clinical
characteristics between respondents and nonrespondents
or patients with unverifiable addresses were compared
with a chi-square or t test. Then, differences in baseline
sociodemographic characteristics between patients who
completed 1 questionnaire and patients who completed
more questionnaires were examined by means of a chi-
square or t test. Furthermore, baseline sociodemographic
characteristics between CRC patients at T1 and an age-
and sex-matched normative population were also com-
pared with a chi-square or t test.
Prevalence rates of symptoms of anxiety and depres-
sion for CRC patients at T1 were compared with the
Dutch normative population with chi-square tests.
The course of reported symptoms of anxiety and
depression by the total group of CRC survivors was ana-
lyzed for anxiety and depression separately with linear
mixed effects models (ie, a covariance pattern model with
an unstructured error covariance matrix and a maximum
likelihood estimation).14 Time was analyzed as a regular
categorical predictor with 4 levels (ie, the 4 time points).
Sociodemographic and clinical variables were analyzed as
time-invariant predictors (ie, baseline characteristics were
used). To correctly interpret all model parameters, all con-
tinuous variables were grand mean–centered.14,15 In addi-
tion, 3 groups were formed on the basis of the survivors’
reported symptoms of anxiety or depression over time:
always reporting symptoms of anxiety or depression (con-
sistently high score 8 on all measurement occasions),
sometimes reporting symptoms of anxiety or depression
(fluctuating score), and never reporting symptoms of anx-
iety or depression (consistently low score 8 on all mea-
surement occasions). We subsequently identified
sociodemographic and clinical factors associated with
group membership with a multinomial logistic regression
analysis (consistently high, fluctuating, and consistently
low reported symptom levels of anxiety or depression).
The impact of symptoms of anxiety and depression
on global quality of life over time was analyzed with lin-
ear mixed effects models.14 Anxiety and depression scores
were analyzed as continuous time-varying predictors14
(separate models and simultaneously), and sex, age, and
number of comorbidities were entered as covariates into
both models. Clinically relevant differences were deter-
mined with the guidelines for interpretation of the
EORTC QLQ-C30.16 Norman’s rule of thumb was
used for the HADS, whereby a 60.5 standard deviation
difference (ie, 1.9 points) indicated a threshold of
discriminating change in scores.17,18 Analyses were
performed in IBM SPSS 24.0 with a significance level of
a5 .05.
RESULTS
Respondents and Nonrespondents at T1
The questionnaire was completed by 73% (n5 2625) at
T1, 83% (n5 1643) at T2, 82% (n5 1458) at T3, and
81% (n5 1241) at T4. Respondents at T1 were signifi-
cantly younger, more often male, more often diagnosed
with stage I disease, and more often treated with radio-
therapy and surgery in comparison with nonrespondents
(all P values< .05; data not shown). Furthermore,
respondents at T1 were more often male and more often
received radiotherapy in comparison with patients with
unverifiable addresses (P< .05; data not shown).
CRC Survivors and Normative Population
In total, 2625 patients with CRC completed the question-
naire at T1. Approximately half (44.9%) were female
(Table 1). The mean age at T1 was 69.4 years with a mean
time since diagnosis of 5.2 years. Colon cancer was diag-
nosed in 61.1%, and approximately one-third of the
patients (29.3%) received chemotherapy in addition to
surgery, whereas 30.6% received radiotherapy in combi-
nation with surgery.
Patients were matched by age and sex with a norma-
tive population. However, the normative population was
on average 2 years younger, reported fewer comorbidities,
was more highly educated, and less often had a partner
than CRC patients (Table 1).
Differences Between CRC Survivors Who
Completed 1 Questionnaire and Those Who
Completed More Than 1 Questionnaire
CRC survivors who completed 1 questionnaire were sig-
nificantly older, were more often female and single, had a
lower educational level, and less often had a job than those
who completed 2 or more questionnaires. In addition,
they were significantly more often diagnosed with 2 or
more comorbid conditions and stage IV disease, they
more often reported symptoms of anxiety (24% vs 19%)
and depression (28% vs 15%), they more often under-
went surgery, and they less often received radiotherapy in
addition to surgery in comparison with those who com-
pleted more questionnaires. No differences were found in
the time since diagnosis or the receipt of chemotherapy in
addition to surgery as the primary treatment (data not
shown).
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Symptoms of Anxiety and Depression in
Comparison With a Normative Population
The baseline prevalence level of depressive symptoms in
CRC patients at T1 was 19.0%, whereas it was 12.8% in
the normative population (P< .01), and the prevalence of
symptoms of anxiety was 20.9% in patients and 11.8% in
the normative population (P< .001; Supporting Fig. 1).
Course of Symptoms of Depression and Anxiety
At the group level, HADS depression scores changed over
time, with the largest change between T1 and T4
(P< .01), although this mean change of 0.89 points was
not clinically relevant (ie, it was not higher than the 0.5
standard deviation difference of 1.9 points; Table 2). No
change was observed in HADS anxiety scores during the 4
assessments. When analyzing the course of depression and
anxiety over time, we simultaneously included informa-
tion on sociodemographics (eg, age and marital status)
and clinical variables (eg, comorbidity and cancer treat-
ment). The results furthermore showed that a longer time
since diagnosis was associated with fewer depressive symp-
toms over time but not anxiety. Older age and being male
were significantly associated with fewer symptoms of anxi-
ety and more symptoms of depression over time. Being
married was associated with fewer symptoms of anxiety
and depression, whereas a low education level and comor-
bid conditions were associated with more symptoms of
anxiety and depression. No association was observed
between radiotherapy, chemotherapy, disease stage, and
HADS anxiety or depression scores over time.
Identifying Subgroups With High Levels of
Symptoms of Depression and Anxiety
When exploring changes within individuals, we saw that
across the 4 time points, 8.3% of the patients with CRC
always reported depressive symptoms (continuously
TABLE 1. Sociodemographic and Clinical Characteristics at Time 1 of CRC Survivors (n52625) and
Respondents From an Age- and Sex-Matched Normative Population (n5315)
CRC Patients Normative Population P
Sex: female, No. (%) 1178 (44.9) 142 (45.1) .95
Age, mean (SD), y 69.4 (9.5) 67.4 (13.2) <.01
Time since diagnosis, mean (SD), y 5.2 (2.8) — NA
Tumor type, No. (%) — NA
Colon 1605 (61.1)
Rectal 1020 (38.9)
Stage, No. (%) — NA
I 780 (29.7)
II 948 (36.1)
III 722 (27.5)
IV 113 (4.3)
Unknown 62 (2.4)
Chemotherapy: yes, No. (%)a 770 (29.3) — NA
Radiotherapy: yes, No. (%)a 802 (30.6) — NA
No. of comorbid conditions, No. (%) .04
0 614 (25.0) 95 (30.2)
1 709 (28.9) 72 (22.9)
2 1129 (46.0) 148 (47.0)
Partner: yes, No. (%) 1984 (76.2) 216 (68.6) .01
Educational level, No. (%)
Low 520 (20.0) 25 (8.0) <.01
Middle 1568 (60.4) 167 (53.3)
High 508 (19.6) 122 (38.9)
Quality of life, mean (SD)b
Global Quality of Life 77.1 (19.1) 77.3 (16.8) .01
Physical Functioning 79.9 (20.7) 85.6 (18.5) .01
Role Functioning 79.7 (27.5) 84.2 (24.7) <.01
Emotional Functioning 85.9 (19.4) 88.5 (15.8) <.01
Cognitive Functioning 84.9 (20.4) 90.5 (15.3) <.01
Social Functioning 86.5 (22.4) 92.2 (17.5) <.01
HADS, mean (SD)
Anxiety 4.6 (3.8) 3.5 (3.3) <.01
Depression 4.4 (3.7) 3.8 (3.0) <.01
Abbreviations: CRC, colorectal cancer; EORTC, European Organisation for Research and Treatment of Cancer; HADS, Hospital Anxiety and Depression Scale;
NA, not applicable; QLQ-C30, Quality of Life Questionnaire Core 30; SD, standard deviation.
a All patients underwent surgery as their primary treatment.
b A higher score on the EORTC QLQ-C30 functional scales and Global Quality of Life scale represent a higher level of function.
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high), 21.1% sometimes experienced depressive symp-
toms (fluctuating), and 70.6% never reported depressive
symptoms (continuously low). Also, 9.6% of the patients
always experienced symptoms of anxiety (continuously
high), 22.3% sometimes experienced these symptoms
(fluctuating), and 68.1% never reported symptoms of
anxiety (continuously low).
Identifying sociodemographic and clinical factors
independently associated with group membership (ie,
continuously high, fluctuating, or continuously low
symptoms of anxiety or depression over time) showed that
a lower number of comorbidities, a higher educational
level, being male, and a lower disease stage were more
often associated with a decreased risk of having fluctuating
or constantly high symptoms of anxiety or depression
(Table 3). More specifically, those with 0 or 1 comorbid
conditions, in comparison with those with 2 or more
comorbidities, had lower risks of reporting fluctuating or
continuously high symptoms of depression or anxiety ver-
sus continuously low symptoms of depression or anxiety
(Table 3). In contrast, those with a low or medium educa-
tional level had a higher risk of fluctuating anxiety scores
and fluctuating or high depression scores. Males had a
lower risk of fluctuating or high levels of anxiety, but no
effect on depression was found. Younger patients had a
higher risk of fluctuating anxiety scores, whereas older
patients had a higher risk of fluctuating depression scores.
Finally, those with stage I disease (vs stage IV disease) had
a lower risk of fluctuating anxiety scores, whereas those
with stage III disease (vs stage IV disease) had a lower risk
of fluctuating depression scores. Chemotherapy or radio-
therapy, the time since diagnosis, and having a partner did
not significantly influence fluctuating or high levels of
anxiety or depression.
Association of Symptoms of Depression and
Anxiety With HRQOL
Higher levels of symptoms of depression and anxiety
were significantly associated with lower values for the
EORTC QLQ-C30 Global Quality of Life, Physical
Functioning, Role Functioning, Cognitive Functioning,
Emotional Functioning, and Social Functioning scales
over time (all P values< .01; Table 4) when we con-
trolled for age, sex, and number of comorbidities.
Depressive symptoms were negatively related to all 6
EORTC QLQ-C30 scales, with the smallest relations for
Physical Functioning (bbetween5 –2.39; bwithin5 –1.00)
and the largest for Role Functioning (bbetween5 –3.31;
bwithin5 –1.96). Likewise, symptoms of anxiety were
negatively related to all 6 EORTC QLQ-C30 scales,
with the smallest relations for Physical Functioning
(bbetween5 –1.49; bwithin5 –0.540) and the largest for
Role Functioning (bbetween5 –3.64; bwithin5 –2.23).
Levels of symptoms of depression and anxiety remained
significantly associated with lower quality of life when
they were simultaneously entered into the model while
we controlled for age, sex, and number of comorbidities.
Those who always reported depressive symptoms
had Global Quality of Life scores that were on average
25.9 to 28.6 points lower than the scores of those never
reporting depressive symptoms (Supporting Fig. 2).
Patients who always reported symptoms of anxiety
reported Global Quality of Life scores that were on aver-
age 20.6 to 23.2 points lower than the scores of patients
never reporting symptoms of anxiety. The aforemen-
tioned differences in quality of life are of large clinical rele-
vance (ie,> 15-point difference).16
DISCUSSION
In the growing population of CRC survivors, more atten-
tion is desired for the psychosocial consequences of CRC.
Although this is a rapidly emerging research area, more
TABLE 2. Times and Sociodemographic and Clini-
cal Factors Associated With HADS Anxiety and
Depression Among Patients With Colorectal
Cancer
HADS
Anxiety
HADS
Depression
Variable b Pa b Pa
Time variables
Time
T4 vs T1 20.06 .42 20.89 <.01
T4 vs T2 0.05 .53 20.42 <.01
T4 vs T3 20.12 .12 20.42 <.01
Time since diagnosisb 20.03 .25 20.05 .05
Sociodemographic variables
Ageb 20.02 .01 0.03 <.01
Sex: male 20.80 <.01 0.38 .02
Married: yes 20.40 .04 20.35 .07
Education
High-low 1.21 <.01 1.53 <.01
High-medium 0.78 <.01 0.96 <.01
Clinical variables
Comorbiditiesb 0.27 <.01 0.22 <.01
Radiotherapy: no 20.06 .74 20.11 .50
Chemotherapy: no 20.10 .65 20.16 .46
Stage
IV vs I 20.86 .07 20.73 .11
IV vs II 20.71 .13 20.60 .18
IV vs III 20.82 .07 20.84 .06
Abbreviations: HADS, Hospital Anxiety and Depression Scale; T1, time 1;
T2, time 2; T3, time 3; T4, time 4.
a Bolded P values are significant.
b Continuous variables are grand mean–centered.
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attention is needed, especially because psychosocial is a
broad concept, and research focusing on long-term CRC
survivors is still relatively scarce.
Our study showed prevalence rates of approximately
1 in 5 for survivors and 1 in 8 for the normative popula-
tion for both anxiety and depressive symptoms.
Prevalence rates were relatively stable across the 4 assess-
ments. On average, 1 in 12 patients reported depressive
symptoms on all 4 assessments, and 1 in 10 always experi-
enced anxiety. A comparison of our observed prevalence
rates with those of other studies was difficult, not only
because of the low number of studies on this topic5 but
TABLE 4. Generalized Linear Mixed Model Estimating Independent Inter- and Intra-Individual Effects of
Depressive and Anxiety Symptoms on Health-Related Quality Of Life
EORTC QLQ-C30 b
Global Quality
of Life
Physical
Functioning
Role
Functioning
Cognitive
Functioning
Emotional
Functioning
Social
Functioning
HADS scales individually
HADS Depression
Depressive symptoms between (inter) 22.75a 22.39a 23.31a 22.85a 23.22a 23.20a
Depressive symptoms within (intra) 21.77a 21.00a 21.96a 21.48a 21.92a 21.83a
HADS Anxiety
Anxiety symptoms between (inter) 22.26a 21.49a 22.31a 22.58a 23.64a 22.51a
Anxiety symptoms within (intra) 21.32a 20.54a 21.10a 21.24a 22.23a 21.44a
HADS scales simultaneously
HADS Anxiety
Anxiety symptoms between (inter) 20.87a 0.13 20.31 21.34a 22.87a 20.80a
Anxiety symptoms within (intra) 20.74a 20.18b 20.38b 20.78a 21.76a 20.86a
HADS Depression
Depressive symptoms between (inter) 22.14a 22.47a 23.08a 21.9a 21.19a 22.64a
Depressive symptoms within (intra) 21.44a 2.91a 21.78a 21.16a 21.17a 21.46a
Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; HADS, Hospital Anxiety and Depression Scale; QLQ-C30, Quality of
Life Questionnaire Core 30.
Continuous variables are grand mean–centered.
aP<.01.
bP<.05.
TABLE 3. Multivariate Analyses: Odds Ratios and 95% Confidence Intervals for the Individual Independent
Variables
Variable
HADS Anxiety HADS Depression
Fluctuating High Fluctuating High
Sex: male vs female 0.66 (0.51-0.84)a 0.52 (0.36-0.75)a 1.11 (0.86-1.44) 1.03 (0.71-1.51)
Age 0.99 (0.97-0.99)b 0.99 (0.97-1.00) 1.02 (1.01-1.04)a 0.99 (0.97-1.01)
Stage
I vs IV 0.49 (0.25-0.99)b 0.88 (0.27-2.84) 0.60 (0.29-1.23) 0.42 (0.16-1.15)
II vs IV 0.57 (0.29-1.12) 1.02 (0.32-3.20) 0.53 (0.26-1.09) 0.43 (0.16-1.14)
III vs IV 0.56 (0.29-1.07) 1.11 (0.37-3.36) 0.45 (0.22-0.88)b 0.51 (0.20-1.28)
Chemotherapy: no vs yes 1.04 (0.73-1.47) 1.04 (0.63-1.73) 0.98 (0.68-1.41) 1.02 (0.60-1.71)
Radiotherapy: no vs yes 0.79 (0.61-1.03) 0.97 (0.66-1.42) 0.89 (0.68-1.17) 0.81 (0.54-1.20)
Time since diagnosis 0.99 (0.95-1.03) 0.96 (0.90-1.02) 0.97 (0.93-1.01) 0.93 (0.87-1.00)
No. of comorbid conditions
0 vs 2 0.44 (0.32-0.61)a 0.35 (0.22-0.57)a 0.51 (0.36-0.71)a 0.21 (0.12-0.37)a
1 vs 2 0.55 (0.41-0.73)a 0.39 (0.25-0.59)a 0.69 (0.51-0.92)a 0.34 (0.21-0.53)a
Educational level
Low vs high 1.64 (1.08-2.48)b 1.80 (0.99-3.27) 2.35 (1.54-3.58)a 3.02 (1.59-5.74)a
Medium vs high 1.43 (1.04-1.96)b 1.52 (0.94-2.46) 1.70 (1.21-2.39)a 2.00 (1.17-3.44)a
Partner: yes vs no 0.92 (0.68-1.25) 0.73 (0.49-1.09) 0.83 (0.61-1.13) 0.65 (0.43-1.00)
Abbreviation: HADS, Hospital Anxiety and Depression Scale.
The odds ratios and 95% confidence intervals (in parentheses) are displayed for patients in a certain category of an independent variable (vs the reference cat-
egory; column) to be in a certain category of a dependent variable (vs the reference category; row).
aP<.01.
bP<.05.
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also because of the wide variation in the studied popula-
tions (eg, stage and time since diagnosis), small sample
sizes, and different cutoffs used.
A shorter time since diagnosis, being male, and older
age were associated with more depressive symptoms.
Interestingly, being male and advanced age were associ-
ated with fewer symptoms of anxiety. Marital status was
associated with fewer symptoms of anxiety and depres-
sion, whereas a low education level and comorbid condi-
tions were associated with more. Our findings are
comparable with the literature on this matter.19-21 An
unexpected finding was that treatment and disease stage
were not associated with symptoms of anxiety and depres-
sion in our study. The literature on this matter is scarce.5
However, disease stage did predict high global distress in
an Australian study of patients with CRC up to 5 years
after their diagnosis.19
As expected, those with high levels of anxiety and
depression reported lower HRQOL across the 4 time
points. However, we did not expect that the differences in
HRQOL between patients who always reported symp-
toms of depression or anxiety and patients who never
reported these symptoms would be so high. Differences
ranged from 25.9 to 28.6 points for depressive symptoms
and from 20.6 to 23.2 points for symptoms of anxiety.
Only 2 other studies examined the association between
the HADS and EORTC QLQ-C30 in patients with
CRC, and they also showed that more symptoms of anxi-
ety and depression were associated with lower
HRQOL.22,23 However, differences in EORTC QLQ-
C30 scale scores between those with low and high levels of
symptoms of anxiety and depression were not presented
in these studies except for the Emotional Functioning
subscale, which was indeed 24 points lower for those with
anxiety and 9.9 points lower for those depressed.22 Our
results show that both depression and anxiety are indepen-
dently related to HRQOL; hence, both psychological fac-
tors have an individual effect on patients’ well-being.
The high prevalence of survivors who reported per-
sisting symptoms of anxiety and depression years after
their diagnosis—approximately 1 in 5—highlights the
importance of screening programs for identifying those
patients in need, even long after the primary treatment
has ended. This immediately sets the first challenge: how
do we identify those in need of help? The results of our
study show that single CRC survivors with 1 or more
comorbid conditions who have a lower educational level
and a high disease stage are most vulnerable to experienc-
ing feelings of depression and anxiety. Second, after suc-
cessful screening, it is vital to know whether these
survivors actually want psychological help to reduce their
feelings of depression and anxiety. In a recent study of
cancer patients, only 36% of distressed patients were will-
ing to accept help for their psychological difficulties.24
Obviously, future research on screening and patients’
need for help is warranted because a significant propor-
tion of patients suffer from feelings of depression and anx-
iety, and they could possibly benefit from psychological
or pharmaceutical treatment. This is especially vital not
only because it is related to poorer HRQOL but also
because one of our previous studies concluded that cancer
survivors (including those with CRC) with depressive
symptoms had a 2-fold risk for all-cause mortality, even
after adjustments for major clinical predictors.25 It is
important to examine whether improvements of feelings
of depression and anxiety would also lead to improved
HRQOL and lower mortality rates among CRC patients.
The current study has a number of limitations that
should be mentioned. First, although information was
present regarding sociodemographic and clinical charac-
teristics of nonrespondents, it remains unknown whether
they declined to participate because of poor health or
depressive feelings. Because depressed patients are less
likely to show initiative and thus answer questionnaires, it
is plausible that a higher proportion of depressed patients
were nonrespondents. Second, although patients were
matched by age and sex to a normative population, the
normative population was significantly younger, reported
fewer comorbidities, was more highly educated, and less
often had a partner than CRC patients. A more optimal
match was not possible. Third, although our study had a
longitudinal study design, it was difficult to determine
causality because associations could also be influenced by
variables not measured. For instance, information on the
prescription of antidepressants or anxiolytics and the use
of professional psychological therapy was not available.
One of the major strengths of this study is the fact that
symptoms of anxiety and depression were assessed pro-
spectively in a large population-based study with a high
response rate, which provides information on their perse-
verance over time in a representative group of CRC
patients. Also, results could be put into perspective by
comparison with an age- and sex-matched normative
population.
In conclusion, approximately 1 in 5 survivors
reported persisting symptoms of anxiety and depression
years after their diagnosis (a rate higher than that for the
normative population, ie, approximately 1 in 8), and these
numbers were quite stable over time. Higher levels of
symptoms of depression and anxiety were independently
Anxiety/Depression in Colorectal Cancer/Mols et al
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associated over time with a lower quality of life. Screening
for these symptoms is, therefore, of the utmost impor-
tance, especially among survivors who are single, have a
low education level, and have comorbid conditions, even
years after their CRC diagnosis and treatment. Proper
referral to mental health specialists is warranted,26,27 not
only because of the symptoms themselves and their associ-
ation with low HRQOL but also because studies have
shown that cancer survivors with depressive symptoms
have an increased risk for all-cause mortality even after
adjustments for major clinical predictors.25,28 In current
clinical practice, the mere question of whether CRC
patients experience feelings of depression or anxiety
should be addressed. Furthermore, providing all CRC
patients with information on where to go when they are in
need of psychological help, not only while being treated
but also after their oncological care discharge, is a vital
first step.
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